Use of microarrays in the clinical practice of pediatric rheumatology: The future is now?

Marilynn Punaro

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations

Abstract

PURPOSE OF REVIEW: Systems immunology is an integrative approach that leverages high throughput technologies as well as mathematical and computational tools to investigate complex immunologic diseases by looking at the state of a system on a comprehensive scale. Gene expression profiling, also known as transcriptomics, measures the expression level of mRNAs (transcripts) in a given cell population at a specific time. Over the past decade, several major gene expression discoveries have been made in pediatric rheumatology, most notably the alpha interferon signature of systemic lupus erythematosus and the interleukin-1 signature in systemic onset juvenile idiopathic arthritis. This article reviews these discoveries, their clinical implications and the recent associated literature. RECENT FINDINGS: Interferon-α has been exploited as a therapeutic target in lupus. Interleukin-1 blockade has been utilized to treat systemic onset juvenile idiopathic arthritis and related autoinflammatory diseases. SUMMARY: Current gene expression studies extend our understanding of the disease pathogenesis of lupus and systemic onset juvenile idiopathic arthritis as well as related conditions. This knowledge has translated to the bedside with implications for clinical practice and direct therapeutic targeting.

Original languageEnglish (US)
Pages (from-to)585-591
Number of pages7
JournalCurrent Opinion in Rheumatology
Volume26
Issue number5
DOIs
StatePublished - Sep 2014

Keywords

  • autoinflammatory diseases
  • gene expression profiling
  • pediatric lupus
  • systemic onset juvenile idiopathic arthritis

ASJC Scopus subject areas

  • Rheumatology

Fingerprint

Dive into the research topics of 'Use of microarrays in the clinical practice of pediatric rheumatology: The future is now?'. Together they form a unique fingerprint.

Cite this